Cam Gallagher, President and CEO, and Pamela Munster, MD, Founder and Chief Scientific Advisor, will present a company overview and clinical update
SAN CARLOS, CA, UNITED STATES, January 7, 2026 /EINPresswire.com/ — Alessa Therapeutics (“Alessa”), a clinical stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, today announced that the Company will be presenting at the 44th Annual J.P. Morgan Healthcare Conference, being held at The Westin St. Francis Hotel in San Francisco, California from January 12-15, 2026.
Cam Gallagher, President and Chief Executive Officer, and Pamela Munster, MD, Founder and Chief Scientific Advisor, will present a company overview and clinical update on Thursday, January 15, 2026 at 7:30 a.m. PT.
About Alessa Therapeutics
Alessa Therapeutics is a clinical-stage biopharmaceutical company pioneering a proprietary drug-delivery technology platform for the sustained and localized release of clinically proven prostate cancer therapies. Developed by researchers at the University of California, San Francisco, Alessa’s patented drug-eluting implants, each about the size of a grain of rice, can provide two or more years of continuous drug elution directly to diseased tissue, thus eliminating the side effects that can result from systemic exposure to certain prostate cancer drugs. Alessa is advancing a pipeline of drug-eluting implants, initially focused on prostate cancer, with the Company’s lead clinical program, Enolen, currently being studied in a Phase 1 clinical trial for the treatment of low to intermediate risk, localized prostate cancer. Founded in 2018, Alessa is backed by leading healthcare investors including Cure Ventures and Mission BioCapital. Learn more at alessatherapeutics.com.
Rachel Ford Hutman
email us here
Ford Hutnam Media
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
